A Multicenter, Single-arm, Open Label Treatment Protocol to Provide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

Trial Profile

A Multicenter, Single-arm, Open Label Treatment Protocol to Provide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Feb 2017

At a glance

  • Drugs Enzalutamide (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; Expanded access
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 02 Jul 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 06 Jan 2013 Planned End Date (31 May 2013) added as reported by Oregon Health and Science University Institutional Review Board.
    • 06 Jan 2013 New source identified and integrated (Oregon Health and Science University Institutional Review Board record: IRB00008613).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top